Passive immunotherapy in Sars-Cov2 infections
This article presents the current situation by November 2021 of the prophylactic or therapeutical use of polyclonal or monoclonal antibodies in Covid-19, either as immuno-modulators, or directly directed towards the virus.
Gespeichert in:
| Veröffentlicht in: | Virologie (Montrouge, France) France), 2021-12, Vol.25 (6), p.324 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | fre |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | 324 |
| container_title | Virologie (Montrouge, France) |
| container_volume | 25 |
| creator | Christodoulou, Ioanna Cohen, Jacques H M |
| description | This article presents the current situation by November 2021 of the prophylactic or therapeutical use of polyclonal or monoclonal antibodies in Covid-19, either as immuno-modulators, or directly directed towards the virus. |
| doi_str_mv | 10.1684/vir.2021.0922 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_35078760</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>35078760</sourcerecordid><originalsourceid>FETCH-LOGICAL-p108t-fae495882fa1daceffe85f49d3360c06dfc2698dcc275eb663c0efc3ad9dc8b3</originalsourceid><addsrcrecordid>eNo1jstKxDAUQLNQZsYZl26lP5B6kzTpzVKKLxhQcPZDmtxgxD5oOoX5ewV1dTibw2HsRkApDFZ3S5pKCVKUYKW8YBshTc3R2GrNrnL-BFAaNa7YWmmosTawYfzN5ZwWKlLXnfph_qDJjeci9cW7mzJvhkX-SCQ_p6HPO3YZ3Vem6z9u2eHx4dA88_3r00tzv-ejAJx5dFRZjSijE8F5ipFQx8oGpQx4MCF6aSwG72WtqTVGeaDolQs2eGzVlt3-ZsdT21E4jlPq3HQ-_m-rb1FRQ4k</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Passive immunotherapy in Sars-Cov2 infections</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Christodoulou, Ioanna ; Cohen, Jacques H M</creator><creatorcontrib>Christodoulou, Ioanna ; Cohen, Jacques H M</creatorcontrib><description>This article presents the current situation by November 2021 of the prophylactic or therapeutical use of polyclonal or monoclonal antibodies in Covid-19, either as immuno-modulators, or directly directed towards the virus.</description><identifier>ISSN: 1267-8694</identifier><identifier>DOI: 10.1684/vir.2021.0922</identifier><identifier>PMID: 35078760</identifier><language>fre</language><publisher>France</publisher><subject>Antibodies, Neutralizing ; COVID-19 ; Humans ; Immunization, Passive ; RNA, Viral ; SARS-CoV-2</subject><ispartof>Virologie (Montrouge, France), 2021-12, Vol.25 (6), p.324</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35078760$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Christodoulou, Ioanna</creatorcontrib><creatorcontrib>Cohen, Jacques H M</creatorcontrib><title>Passive immunotherapy in Sars-Cov2 infections</title><title>Virologie (Montrouge, France)</title><addtitle>Virologie (Montrouge)</addtitle><description>This article presents the current situation by November 2021 of the prophylactic or therapeutical use of polyclonal or monoclonal antibodies in Covid-19, either as immuno-modulators, or directly directed towards the virus.</description><subject>Antibodies, Neutralizing</subject><subject>COVID-19</subject><subject>Humans</subject><subject>Immunization, Passive</subject><subject>RNA, Viral</subject><subject>SARS-CoV-2</subject><issn>1267-8694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1jstKxDAUQLNQZsYZl26lP5B6kzTpzVKKLxhQcPZDmtxgxD5oOoX5ewV1dTibw2HsRkApDFZ3S5pKCVKUYKW8YBshTc3R2GrNrnL-BFAaNa7YWmmosTawYfzN5ZwWKlLXnfph_qDJjeci9cW7mzJvhkX-SCQ_p6HPO3YZ3Vem6z9u2eHx4dA88_3r00tzv-ejAJx5dFRZjSijE8F5ipFQx8oGpQx4MCF6aSwG72WtqTVGeaDolQs2eGzVlt3-ZsdT21E4jlPq3HQ-_m-rb1FRQ4k</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Christodoulou, Ioanna</creator><creator>Cohen, Jacques H M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20211201</creationdate><title>Passive immunotherapy in Sars-Cov2 infections</title><author>Christodoulou, Ioanna ; Cohen, Jacques H M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p108t-fae495882fa1daceffe85f49d3360c06dfc2698dcc275eb663c0efc3ad9dc8b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2021</creationdate><topic>Antibodies, Neutralizing</topic><topic>COVID-19</topic><topic>Humans</topic><topic>Immunization, Passive</topic><topic>RNA, Viral</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Christodoulou, Ioanna</creatorcontrib><creatorcontrib>Cohen, Jacques H M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Virologie (Montrouge, France)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Christodoulou, Ioanna</au><au>Cohen, Jacques H M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Passive immunotherapy in Sars-Cov2 infections</atitle><jtitle>Virologie (Montrouge, France)</jtitle><addtitle>Virologie (Montrouge)</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>25</volume><issue>6</issue><spage>324</spage><pages>324-</pages><issn>1267-8694</issn><abstract>This article presents the current situation by November 2021 of the prophylactic or therapeutical use of polyclonal or monoclonal antibodies in Covid-19, either as immuno-modulators, or directly directed towards the virus.</abstract><cop>France</cop><pmid>35078760</pmid><doi>10.1684/vir.2021.0922</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1267-8694 |
| ispartof | Virologie (Montrouge, France), 2021-12, Vol.25 (6), p.324 |
| issn | 1267-8694 |
| language | fre |
| recordid | cdi_pubmed_primary_35078760 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Antibodies, Neutralizing COVID-19 Humans Immunization, Passive RNA, Viral SARS-CoV-2 |
| title | Passive immunotherapy in Sars-Cov2 infections |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T15%3A54%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Passive%20immunotherapy%20in%20Sars-Cov2%20infections&rft.jtitle=Virologie%20(Montrouge,%20France)&rft.au=Christodoulou,%20Ioanna&rft.date=2021-12-01&rft.volume=25&rft.issue=6&rft.spage=324&rft.pages=324-&rft.issn=1267-8694&rft_id=info:doi/10.1684/vir.2021.0922&rft_dat=%3Cpubmed%3E35078760%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35078760&rfr_iscdi=true |